9 years of historical data (2017–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Revolution Medicines, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $20.1B | $15.1B | $7.3B | $3.2B | $1.9B | $1.8B | $2.6B | — | — | — |
| Enterprise Value | $19.9B | $14.9B | $6.9B | $2.6B | $1.8B | $1.8B | $2.6B | — | — | — |
| P/E Ratio → | -17.15 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 280.24 | 54.28 | 62.35 | 61.34 | — | — | — |
| P/B Ratio | 11.89 | 9.28 | 3.24 | 1.78 | 2.80 | 3.04 | 5.55 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 227.71 | 51.54 | 60.93 | 59.68 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -58.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | — | — | — | -4207.1% | -730.0% | -639.7% | -257.5% | -108.2% | -200.0% | — |
| Net Profit Margin | — | — | — | -3768.3% | -703.0% | -636.6% | -251.6% | -95.2% | -207.2% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -58.1% | -29.3% | -34.8% | -38.6% | -34.7% | -34.5% | -38.3% | -82.6% | -687.0% |
| ROA | -46.1% | -46.1% | -26.0% | -30.4% | -32.1% | -28.7% | -27.5% | -24.4% | -45.0% | -206.5% |
| ROIC | -54.3% | -54.3% | -33.6% | -40.5% | -33.7% | -29.3% | -30.8% | -49.8% | -266.8% | — |
| ROCE | -53.0% | -53.0% | -32.0% | -36.5% | -36.2% | -31.4% | -31.7% | -34.1% | -54.7% | -416.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $384M exceeds total debt of $159M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.06 | 0.05 | 0.09 | 0.11 | 0.07 | — | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.18 | -0.33 | -0.14 | -0.07 | -0.15 | -0.11 | -0.72 | -2.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -48.80 | -48.80 | — | -1607.87 | — | -15667.33 | -1559.11 | -510.57 | -347.66 | -302.22 |
Net cash position: cash ($384M) exceeds total debt ($159M)
Short-term solvency ratios and asset-utilisation metrics
Revolution Medicines, Inc.'s current ratio of 7.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.06x to 7.14x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.14 | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.80 | 1.24 |
| Quick Ratio | 7.14 | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.58 | 1.24 |
| Cash Ratio | 6.97 | 6.97 | 13.97 | 12.88 | 10.40 | 9.56 | 9.34 | 2.85 | 2.28 | 1.19 |
| Asset Turnover | — | — | — | 0.01 | 0.04 | 0.04 | 0.08 | 0.23 | 0.12 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 39.53 | 48.21 | 73.63 | 54.29 | 63.73 | 132.19 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Revolution Medicines, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $190M | $168M | $113M | $81M | $73M | $67M | $36M | $36M | $36M |
Compare RVMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| RVMDYou | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| RCUS | $3B | -6.2 | — | — | — | -156.3% | -63.3% | -64.1% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RVMD stacks up against sector leader Incyte Corporation.
Start ComparisonRevolution Medicines, Inc.'s current P/E ratio is -17.1x. This places it at the 50th percentile of its historical range.
Revolution Medicines, Inc.'s return on equity (ROE) is -58.1%. The historical average is -43.9%.
Based on historical data, Revolution Medicines, Inc. is trading at a P/E of -17.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.